Adage Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

Adage Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.7M	Buy	+66,500	New	+$15.5M	0.02%	551
2025 Q3	–	Sell	-459,606	Closed	-$79.3M	–	886
2025 Q2	$79.3M	Buy	459,606 +132,201	+40%	+$21.5M	0.13%	152
2025 Q1	$51M	Buy	+327,405	New	+$46.8M	0.09%	222
2024 Q4	–	Sell	-486,957	Closed	-$72.7M	–	878
2024 Q3	$72.7M	Sell	486,957 -333,555	-41%	-$45M	0.13%	165
2024 Q2	$112M	Buy	820,512 +611,000	+292%	+$83.1M	0.21%	94
2024 Q1	$31.7M	Buy	209,512 +65,512	+45%	+$9.35M	0.06%	339
2023 Q4	$18.1M	Sell	144,000 -382,371	-73%	-$38.1M	0.04%	450
2023 Q3	$49.3M	Sell	526,371 -162,629	-24%	-$15.2M	0.11%	200
2023 Q2	$61.5M	Buy	689,000 +189,000	+38%	+$16.4M	0.13%	169
2023 Q1	$53.6M	Sell	500,000 -140,000	-22%	-$16M	0.12%	201
2022 Q4	$78.2M	Buy	640,000 +410,000	+178%	+$47.6M	0.19%	131
2022 Q3	$23.8M	Buy	230,000 +65,000	+39%	+$6.16M	0.06%	359
2022 Q2	$15.3M	Sell	165,000 -7,000	-4%	-$660K	0.04%	536
2022 Q1	$20.2M	Buy	172,000 +122,000	+244%	+$14.1M	0.04%	447
2021 Q4	$6.73M	Buy	+50,000	New	+$7.44M	0.01%	784
2020 Q3	–	Sell	-30,000	Closed	-$4.44M	–	756
2020 Q2	$4.44M	Sell	30,000 -10,000	-25%	-$1.37M	0.01%	637
2020 Q1	$4.5M	Hold	40,000	–	–	0.01%	584
2019 Q4	$5.57M	Sell	40,000 -160,000	-80%	-$17.8M	0.01%	600
2019 Q3	$19.3M	Sell	200,000 -50,000	-20%	-$5.58M	0.05%	376
2019 Q2	$28.8M	Buy	250,000 +25,000	+11%	+$2.99M	0.07%	300
2019 Q1	$26.5M	Sell	225,000 -100,000	-31%	-$8.76M	0.07%	318
2018 Q4	$20.4M	Buy	325,000 +75,000	+30%	+$4.71M	0.06%	321
2018 Q3	$17.7M	Buy	250,000 +25,000	+11%	+$1.72M	0.04%	428
2018 Q2	$15M	Sell	225,000 -350,000	-61%	-$23M	0.03%	474
2018 Q1	$37.6M	Buy	575,000 +556,000	+2,926%	+$31.2M	0.09%	274
2017 Q4	$761K	Buy	+19,000	New	+$691K	﹤0.01%	684

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Adage Capital Partners's ASND Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 66,500 shares worth $17.7M. The stake represents 0.02% of the portfolio and ranks #551 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in ASND as recently as Q2 2025.

Adage Capital Partners first reported a position in ASND in Q4 2017 and has held it in 26 quarters since. The position peaked at $112M in Q2 2024. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Adage Capital Partners held 66,500 shares of Ascendis Pharma A/S worth $17.7M as of Q2 2026.
Ascendis Pharma A/S was a new Adage Capital Partners position in Q2 2026.
Ascendis Pharma A/S made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #551 holding.
Adage Capital Partners first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 26 quarters since.
Adage Capital Partners's Ascendis Pharma A/S position peaked at $112M in Q2 2024.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.